Premium
Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment
Author(s) -
Litvan Irene,
Kieburtz Karl,
Tröster Alexander I.,
Aarsland Dag
Publication year - 2018
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.27345
Subject(s) - dementia , clinical trial , parkinson's disease , quality of life (healthcare) , cognition , disease , cognitive impairment , medicine , intervention (counseling) , physical medicine and rehabilitation , physical therapy , psychology , psychiatry , nursing
Treatments to slow the progression of cognitive dysfunction to dementia and improve the quality of life of persons with Parkinson's disease (PD) are desperately needed. Because PD mild cognitive impairment is considered a transitional stage before dementia, it opens a window to timely intervention. This article critically reviews the strengths and challenges of pharmacologic and nonpharmacologic clinical therapeutic trials in PD mild cognitive impairment conducted during the past 5 years, including ongoing trials. Relatively few high‐quality trials have been conducted, and some important factors in designing future clinical trials are discussed. © 2018 International Parkinson and Movement Disorder Society